COURT SHOOTS DOWN GENERIC FOR LIPITOR

Published Online: Tuesday, May 1, 2007

Hopes for the introduction of a generic version of Pfizer's Lipitor (atorvastatin calcium) suffered a setback as the Supreme Court declined to intervene in Ranbaxy Laboratories Ltd's challenge of a lower-court decision that upheld Pfizer's patent for the blockbuster cholesterol-lowering drug. The US patent for Lipitor is not due to expire until March 2010, but Ranbaxy had sought to market a generic version prior to that date. The Supreme Court's action shuts the door on that effort.

Ranbaxy's litigation was not entirely fruitless, however. The Supreme Court ruling also let stand previous action by a lower court that effectively whittled down Lipitor's patent protection by 15 months. Pfizer is currently seeking a ruling from the US Patent and Trademark Office that would restore Lipitor's patent through June 2011.




Latest Articles
Pharmacists might be surprised to learn that Pinterest is a hotbed for anti-vaccine sentiment.
The FDA has approved betamethasone dipropionate spray, 0.05%, as a treatment for mild to moderate plaque psoriasis in patients aged 18 years and older.
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Latest Issues
$auto_registration$
VSEO N/A